Study S000356
A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine With Metformin in Japanese Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
Registration
Registered primary outcomes
- Change from baseline in HbA1c [Baseline, 26 weeks]
Linked records (3)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0008233 | iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP-L trial. Yabe D, Journal of diabetes investigation | 2021 | Other trial | PMID 33945227DOI | cites ClinicalTrials.gov:NCT02752412 |
| R0012880 | Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial. Kaneto H, Diabetes, obesity & metabolism | 2020 | Randomized trial | PMID 32072742DOI | cites ClinicalTrials.gov:NCT02752412; registry reference RESULT:32072742 |
| R0012993 | Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials. Terauchi Y, Diabetes, obesity & metabolism | 2020 | Other trial | PMID 33404200DOI | cites ClinicalTrials.gov:NCT02752412 |